ClinicalTrials.gg
TerminatedNCT03675126Updated Sep 19, 2024Results posted

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

A Phase 1/2 interventional study of SRP-5051 in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Terminated at 8 sites in 2 countries. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
The sponsor has decided to integrate 5051-102 into 5051-201. Participants from 5051-102 will be eligible to enroll in 5051-201 Part B.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
4 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
16th of 25
15 · median 24
Started
2018
with 4 others
Phase 1/2
5 of 27
none open now
Registered
14th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 14th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.

03

Conditions studied

  • Muscular Dystrophy, Duchenne

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
  • DMD
  • Exon 51
  • Ambulatory
  • Pediatric
  • Nonambulatory
  • Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)
  • Duchenne
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed a study of SRP-5051 and continues to meet the Eligibility Criteria of Study 5051-102.

Exclusion criteria

Exclusion Criteria:

  • Initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) since completing a study administering SRP-5051 and while participating in this study for any of the following: angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs), beta-blockers, potassium and *.
  • Requires antiarrhythmic and/or diuretic therapy for heart failure.
  • Use of any herbal medication/supplement containing aristolochic acid.
  • Treatment with any experimental therapy since entering original study or any experimental gene therapy for the treatment of DMD at any time.
  • Participation in an interventional clinical trial since completing original study.

Other inclusion/exclusion criteria apply.

* The dose of steroids must remain constant except for modifications to accommodate changes in weight.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    SRP-5051

    Participants will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.

    Drug: SRP-5051

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    A TEAE was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Up to approximately 135 weeks

Secondary outcomes

  1. Plasma Concentration of SRP-5051

    For pharmacokinetic (PK) analysis, plasma samples were collected pre-dose (approximately 30 minutes prior to the start of infusion), immediately prior to the end of infusion (prior to flush), and approximately 4 to 6 hours after the end of dosing. Results are reported in micrograms/liter (ug/L) and are presented as an average across the days specified in the time frame.

    Time frame: Day 1, Day 84, every 84 days after Day 84 (up to a maximum of approximately 135 weeks) (pre-dose, immediately prior to end of infusion, up to 4-6 hours post-dose)

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneSRP-5051
Started15
Received at least 1 dose of study drug15
Completed0
Not completed15
Withdrew: Study terminated by sponsor9
Withdrew: Death2
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

A TEAE was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Up to approximately 135 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
ParticipantsSRP-5051
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)14
SecondaryPlasma Concentration of SRP-5051

For pharmacokinetic (PK) analysis, plasma samples were collected pre-dose (approximately 30 minutes prior to the start of infusion), immediately prior to the end of infusion (prior to flush), and approximately 4 to 6 hours after the end of dosing. Results are reported in micrograms/liter (ug/L) and are presented as an average across the days specified in the time frame.

Time frame:
Day 1, Day 84, every 84 days after Day 84 (up to a maximum of approximately 135 weeks) (pre-dose, immediately prior to end of infusion, up to 4-6 hours post-dose)
Reported as:
Mean · ug/L
Plasma Concentration of SRP-5051
ug/LSRP-5051
Pre-dose486.25 ± 7717.595
End of Infusion45244.93 ± 42639.411
4-6 Hours Post-dose2790.32 ± 10941.464

Adverse events

Collected over Up to approximately 135 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SRP-50512/15 (13.3%)6/15 (40%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSRP-5051
HypomagnesaemiaMetabolism and nutrition disorders2/15
AnaemiaBlood and lymphatic system disorders1/15
Cardiac arrestCardiac disorders1/15
Cardiogenic shockCardiac disorders1/15
CardiomyopathyCardiac disorders1/15
Colitis ischaemicGastrointestinal disorders1/15
IleusGastrointestinal disorders1/15
DehydrationMetabolism and nutrition disorders1/15
Electrolyte imbalanceMetabolism and nutrition disorders1/15
HypokalaemiaMetabolism and nutrition disorders1/15
Most frequent other events
Showing 10 of 86
Most frequent other events
EventSRP-5051
HypomagnesaemiaMetabolism and nutrition disorders7/15
CoughRespiratory, thoracic and mediastinal disorders5/15
ContusionInjury, poisoning and procedural complications3/15
FallInjury, poisoning and procedural complications3/15
Back painMusculoskeletal and connective tissue disorders3/15
Nasal congestionRespiratory, thoracic and mediastinal disorders3/15
Abdominal painGastrointestinal disorders2/15
DiarrhoeaGastrointestinal disorders2/15
DysphagiaGastrointestinal disorders2/15
Gastrooesophageal reflux diseaseGastrointestinal disorders2/15

Baseline characteristics

Safety Set: all participants who started the study drug infusion.

Age, Continuous
Age, Continuous(years)SRP-5051
Mean16.5 ± 2.80
Sex: Female, Male
Sex: Female, Male(Participants)SRP-5051
Female0
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SRP-5051
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SRP-5051
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American2
White9
More than one race0
Unknown or Not Reported1
08

Study locations

8 sites
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • NW FL Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Center for Integrative Rare Disease Research (CIRDR)
    Atlanta, Georgia 30318, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75207, United States
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Aug 2021, 32 months.

Results were first posted in Sep 2024, 3 years after primary completion. A results delay was requested in Aug 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Sep 18, 2018
StartActual
Dec 19, 2018
Primary completionActual
Aug 25, 2021
CompletionActual
Aug 25, 2021
Results delay requested
Aug 22, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03675126
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Dec 19, 2018
Primary completion
Aug 25, 2021
Completion
Aug 25, 2021
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vesleteplirsen

Start the discussion